The topical drug, which is applied directly to inflamed skin, is now being tested in a multicenter clinical trial in patients with eczema
cGAMP binds to stimulator of interferon genes (STING), which further activates interferon regulatory factors 3 and 7 (IRF3, IRF7) that drive type I IFN expression or nuclear factor kappa-light-chain-enhancer of activated B-cell (NF-B) that induces the expression of proinflammatory genes (101104)
Reduces Inflammation and Oxidative Stress This directly slows CKD progression
Different forms exist oral, liposomal, topical, and IV but oral and Setria glutathione are best supported by research for safety and bioavailability
References Uribe PM, Kawas LH, Harding JW, Coffin AB
Hives, facial swelling, throat tightness, or breathing trouble requires immediate emergency care